Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

Brief pain inventory; LANSS: Leeds assessment of neuropathic symptoms and signs; MPQ: McGill pain questionnaire; NPS: Neuropathic pain scale; NRS: Numerical rating scale; VAS: Visual analog score.

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal ...

Accurate pain reporting in sickle cell disease is critical to effective pain assessment and management, but accuracy depends on patient comprehension of forms.

Brief pain inventory; LANSS: Leeds assessment of neuropathic symptoms and signs; MPQ: McGill pain questionnaire; NPS: Neuropathic pain scale; NRS: Numerical rating scale; VAS: Visual analog score.

After failing on these conservative therapies -- including physical therapy, nonsteroidal anti-inflammatory drugs, acetaminophen, drugs for neuropathic pain ... Visual Analog Scale, over sham ...

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of moderate-to-severe acute pain following full abdominoplasty – a cosmetic surgery ...